Rocket One closed at $0.44 on Nov 4, down 4.33%, within 0.0% of its lowest close since Sep 11. Volume of 321.4K shares was 0.96× its 20-day average (close to normal).
Split-adjusted performance: -37.0% over one month.
Short interest was 734.4K shares at the Oct 15 settlement, down 26.0% from the prior report (3.6% of float, 2.2 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| RKTORocket One | $0.4422 | −4.33% | — | — | — | — | $11.0M | |
| PTNPalatin Technologies | $6.02 | +15.33% | −68.3% | — | −1449.1% | — | $10.7M | Compare |
| LSTALisata Therapeutics | $1.06 | −2.75% | −67.5% | −100.0% | — | — | $11.5M | Compare |
| TVRDTvardi Therapeutics | $0.8614 | +3.17% | −76.5% | — | — | — | $11.5M | Compare |
| CLRBCellectar Biosciences INC NEW | $1.23 | −6.11% | −65.2% | — | — | — | $11.6M | Compare |
| BIVIBioVie | $1.34 | −22.54% | −19.3% | — | — | — | $11.6M | Compare |
| ASBPAspire-Lakewood Holdings | $7.31 | +0.55% | +31.0% | — | −2009.6% | — | $10.3M | Compare |
| LPCNLipocine | $1.44 | −1.37% | −40.7% | −100.0% | — | — | $11.9M | Compare |
| PHIOPhio Pharmaceuticals | $0.8699 | −3.67% | −24.4% | — | — | — | $10.1M | Compare |
No recent articles focused on Rocket One. 1 articles mention it in passing.
Rocket One Inc is focused on developing and commercializing infrastructure for the orbital economy, including next-generation nanomagnetic AI chip technology designed for radiation-tolerant, energy-constrained environments such as low-Earth orbit, deep-space platforms, and defense systems. The company also intends to pursue opportunities related to nano-launch systems and nanosatellite deployment. In addition, its biotechnology operations, conducted through a wholly owned subsidiary, include development programs such as HT-001, HT-KIT, HT-ALZ, and a GDNF-based metabolic program.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
